Becton Dickinson: revenue +5.4% but earnings -34.3%, internal cost issue
FROM THE WIRE · FINANCE.YAHOO.COM
Becton, Dickinson and Company (NYSE:BDX) closed at $188.89 on October 12. The stock has returned over 21.5% during the last six months, compared to a 21.25% return for the Insider Monkey Billionaire Index and 14% for State Street SPDR S&P 500 ETF Trust. A medical device maker…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishProfit collapse despite revenue growth signals margin pressure that could weigh on the stock valuation.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Becton Dickinson reported 5.4% revenue growth but 34.3% earnings decline.
- 02The issue is internal cost management, not market demand weakness.
- 03Demand for syringes and catheters remains stable across economic cycles.
- 04BDX ranks among the 10 best blue chip dividend stocks in the analysis.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Becton, Dickinson and Company187.37 USDMarket closedtoday -0.80%Negative State Street SPDR S&P 500 ETF778.05 USDMarket closedtoday -0.01%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets